Additionally, tumor cells within an immunosuppressive TME release inhibitory molecules like PD-L1 and exhibit functional genetic mutations in key pathways such as PTEN/PI3K, CDK4–CDK6, MAPK, EGFR, and KRAS. Here, PTEN is linked to neoplasm.